Search

Your search keyword '"Donini, Maddalena"' showing total 97 results
Start Over Author "Donini, Maddalena"
97 results on '"Donini, Maddalena"'

1. Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review.

Author

Giudice, Giulia Claire, Maffezzoli, Michele, Testi, Irene, Acunzo, Alessandro, Agnetti, Virginia, Tuttobene, Pietro, Donini, Maddalena, Massari, Francesco, Mollica, Veronica, Rizzo, Alessandro, and Buti, Sebastiano

Abstract

Introduction: Metastasis-directed treatment (MDT) is progressively expanding its scope in the treatment of metastatic renal cell carcinoma (mRCC), finding application both in cases of oligometastatic disease, whether synchronous or metachronous, and in oligo-progression during systemic therapy (ST). This updated narrative review incorporates recent advancements in managing oligometastatic and oligo-progressive RCC. A PubMed literature search using keywords related to mRCC and its treatments was made. Observational studies, clinical trials, and reviews were analyzed, selecting the most relevant articles based on evidence strength. Areas covered: We analyzed the current role of surgery, both on the primary than on metastatic sites, and the recent advantages in both radiotherapy, ST and focal therapies. Lastly, we focused on single metastatic sites of interest. Expert opinion: Nowadays personalized tailored treatments are the key, integrating multimodal approaches like metastasectomy, radiotherapy, and ST. While the role of cytoreductive nephrectomy remains debated, metastasectomy and radiotherapy demonstrates potential in managing both oligometastatic and oligo-progressive disease, either alone or in synergy with ST, though more robust evidence is needed. Future research should focus on identifying biomarkers for treatment selection, optimizing therapy timing, and refining patient stratification to enhance outcomes. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

2. Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer

Author

Caffo, Orazio, Gasparro, Donatello, Di Lorenzo, Giuseppe, Volta, Alberto Dalla, Guglielmini, Pamela, Zucali, Paolo, Bortolus, Roberto, Cavo, Alessia, Ceresoli, Giovanni, Chiari, Rita, Fornarini, Giuseppe, Fratino, Lucia, Iaculli, Alessandro, Maruzzo, Marco, Masini, Cristina, Morelli, Franco, Mucciarini, Claudia, Procopio, Giuseppe, Sabbatini, Roberto, Verri, Elena, Kinspergher, Stefania, Maines, Francesca, Messina, Carlo, Veccia, Antonello, and Donini, Maddalena

Published
2020
Full Text
View/download PDF

3. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study

Author

Procopio, Giuseppe, Apollonio, Giulia, Cognetti, Francesco, Miceli, Rosalba, Milella, Michele, Mosca, Alessandra, Chiuri, Vincenzo Emanuele, Bearz, Alessandra, Morelli, Franco, Ortega, Cinzia, Atzori, Francesco, Donini, Maddalena, Ratta, Raffaele, Raimondi, Alessandra, Claps, Melanie, Martinetti, Antonia, Capitanio, Umberto, de Braud, Filippo G., Cappelletti, Vera, and Verzoni, Elena

Published
2019
Full Text
View/download PDF

4. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme

Author

Maines, Francesca, Caffo, Orazio, De Giorgi, Ugo, Fratino, Lucia, Lo Re, Giovanni, Zagonel, Vittorina, D'Angelo, Alessandro, Donini, Maddalena, Verderame, Francesco, Ratta, Raffaele, Procopio, Giuseppe, Campadelli, Enrico, Massari, Francesco, Gasparro, Donatello, Ermacora, Paola, Messina, Caterina, Giordano, Monica, Alesini, Daniele, Basso, Umberto, Fraccon, Anna Paola, Vicario, Giovanni, Conteduca, Vincenza, and Galligioni, Enzo

Published
2016
Full Text
View/download PDF

5. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

Author

Pignata, Sandro, primary, Scambia, Giovanni, additional, Schettino, Clorinda, additional, Arenare, Laura, additional, Pisano, Carmela, additional, Lombardi, Davide, additional, De Giorgi, Ugo, additional, Andreetta, Claudia, additional, Cinieri, Saverio, additional, De Angelis, Carmine, additional, Priolo, Domenico, additional, Casanova, Claudia, additional, Rosati, Marta, additional, Greco, Filippo, additional, Zafarana, Elena, additional, Schiavetto, Ilaria, additional, Mammoliti, Serafina, additional, Cecere, Sabrina Chiara, additional, Salutari, Vanda, additional, Scalone, Simona, additional, Farolfi, Alberto, additional, Di Napoli, Marilena, additional, Lorusso, Domenica, additional, Gargiulo, Piera, additional, Califano, Daniela, additional, Russo, Daniela, additional, Spina, Anna, additional, De Cecio, Rossella, additional, Chiodini, Paolo, additional, Perrone, Francesco, additional, Accinno, Valentina, additional, Altavilla, Chiara, additional, Antonelli, Giovanna, additional, Artioli, Grazia, additional, Avola, Francesco, additional, Barbara, Bonifacio, additional, Barbato, Valentina, additional, Bartoletti, Michele, additional, Bevilacqua, Simona, additional, Bordonaro, Roberto, additional, Borghese, Oriana, additional, Buonfanti, Gaetano, additional, Camarda, Floriana, additional, Canzanella, Giuliana, additional, Carbone, Vittoria, additional, Carbone, Maria Rita, additional, Carlo Stella, Giulia, additional, Cassani, Chiara, additional, Castagna, Fabrizio, additional, Cattaneo, Monica, additional, Cinefra, Margherita, additional, Colombo, Nicoletta, additional, Corsetti, Serena, additional, Dall'Agata, Monia, additional, D'Amico, Maria, additional, Daniele, Gennaro, additional, De Marino, Elvira, additional, De Matteis, Giovanni, additional, De Placido, Sabino, additional, Del Bene, Gabriella, additional, Del Giudice, Antonia, additional, Del Monte, Francesca, additional, Del Sesto, Michele, additional, Donini, Maddalena, additional, Drudi, Giuliana, additional, Falcone, Gianluca, additional, Favaretto, Adolfo, additional, Ferrera, Giulia, additional, Florio, Manuela, additional, Forestieri, Valeria, additional, Gallo, Maria Stella, additional, Gallo, Ciro, additional, Garibaldi, Francesca, additional, Gerevini, Fabiana, additional, Ghizzoni, Viola, additional, Giganti, Maria Olga, additional, Gimigliano, Anna, additional, Giudice, Elena, additional, Gnocchi, Nicoletta, additional, Gravina, Adriano, additional, Greggi, Stefano, additional, Iaia, Maria Laura, additional, Ilardi, Annalisa, additional, Iovine, Gelsomina, additional, Ippoliti, Gabriella, additional, Irollo, Giulia, additional, Isidori, Ilenia, additional, Lapresa, Mariateresa, additional, Lavenia, Giuseppe, additional, Longhitano, Laura, additional, Lucia, Bortot, additional, Luzi, Gabriella, additional, Mariano, Sara, additional, Marino, Valentina, additional, Marrapese, Giovanna, additional, Martino, Marilena, additional, Matocci, Roberta, additional, Mazzoni, Enrica, additional, Mercuri, Daniela, additional, Mirto, Maria, additional, Mollo, Giovanna, additional, Montinaro, Abbondanza, additional, Moscatelli, Marta, additional, Mosconi, Anna Maria, additional, Musacchio, Lucia, additional, Nanni, Nicoletta, additional, Natalucci, Pamela, additional, Nicoloso, Milena Sabrina, additional, Orditura, Michele, additional, Parma, Gabriella Maria, additional, Passalacqua, Rodolfo, additional, Pelone, Michela, additional, Perri, Maria Teresa, additional, Perrucci, Bruno, additional, Piancastelli, Alessandra, additional, Piccirillo, Maria Carmela, additional, Piccolo, Antonio, additional, Pignata, Sandro, additional, Rapisardi, Stefania, additional, Ravaglia, Giorgia, additional, Ribecco, Teresa, additional, Ricci, Caterina, additional, Roccio, Marianna, additional, Romano, Fiorella, additional, Sambataro, Daniela, additional, Savio, Alfonso, additional, Sbriglia, Ada, additional, Scaffa, Cono, additional, Sergi, Concetta, additional, Sgandurra, Francesca, additional, Sorio, Roberto, additional, Stabile, Stefano, additional, Tabaro, Gianna, additional, Tambaro, Margherita, additional, Tamberi, Stefano, additional, Tecchiato, Angelica, additional, Trujillo, Angela Maria, additional, and Zaccarelli, Eleonora, additional

Published
2023
Full Text
View/download PDF

6. Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study

Author

Brunelli, Matteo, primary, Martignoni, Guido, additional, Malpeli, Giorgio, additional, Volpe, Alessandro, additional, Cima, Luca, additional, Raspollini, Maria Rosaria, additional, Barbareschi, Mattia, additional, Tafuri, Alessandro, additional, Masi, Giulia, additional, Barzon, Luisa, additional, Ammendola, Serena, additional, Villanova, Manuela, additional, Cerruto, Maria Angela, additional, Milella, Michele, additional, Buti, Sebastiano, additional, Bersanelli, Melissa, additional, Fornarini, Giuseppe, additional, Rebuzzi, Sara Elena, additional, Vellone, Valerio Gaetano, additional, Gaggero, Gabriele, additional, Procopio, Giuseppe, additional, Verzoni, Elena, additional, Bracarda, Sergio, additional, Fanelli, Martina, additional, Sabbatini, Roberto, additional, Passalacqua, Rodolfo, additional, Perrucci, Bruno, additional, Giganti, Maria Olga, additional, Donini, Maddalena, additional, Panni, Stefano, additional, Tucci, Marcello, additional, Prati, Veronica, additional, Ortega, Cinzia, additional, Caliò, Anna, additional, Eccher, Albino, additional, Alongi, Filippo, additional, Pappagallo, Giovanni, additional, Iacovelli, Roberto, additional, Mosca, Alessandra, additional, Umari, Paolo, additional, Montagnani, Ilaria, additional, Gobbo, Stefano, additional, Atzori, Francesco, additional, Munari, Enrico, additional, Maruzzo, Marco, additional, Basso, Umberto, additional, Pierconti, Francesco, additional, Patriarca, Carlo, additional, Colombo, Piergiuseppe, additional, Lapini, Alberto, additional, Conti, Giario, additional, Salvioni, Roberto, additional, Bollito, Enrico, additional, Cossarizza, Andrea, additional, Massari, Francesco, additional, Rizzo, Mimma, additional, Franco, Renato, additional, Zito-Marino, Federica, additional, Aberasturi Plata, Yoseba, additional, Galuppini, Francesca, additional, Sbaraglia, Marta, additional, Fassan, Matteo, additional, Dei Tos, Angelo Paolo, additional, Colecchia, Maurizio, additional, Moch, Holger, additional, Scaltriti, Maurizio, additional, Porta, Camillo, additional, Delahunt, Brett, additional, Giannarini, Gianluca, additional, Bortolus, Roberto, additional, Rescigno, Pasquale, additional, Banna, Giuseppe Luigi, additional, Signori, Alessio, additional, Obispo, Miguel Angel Llaja, additional, Perris, Roberto, additional, and Antonelli, Alessandro, additional

Published
2022
Full Text
View/download PDF

8. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme

Author

Caffo, Orazio, De Giorgi, Ugo, Fratino, Lucia, Lo Re, Giovanni, Basso, Umberto, DʼAngelo, Alessandro, Donini, Maddalena, Verderame, Francesco, Ratta, Raffaele, Procopio, Giuseppe, Campadelli, Enrico, Massari, Francesco, Gasparro, Donatello, Macrini, Sveva, Messina, Caterina, Giordano, Monica, Alesini, Daniele, Zustovich, Fable, Fraccon, Anna P., Vicario, Giovanni, Conteduca, Vincenza, Maines, Francesca, and Galligioni, Enzo

Published
2015
Full Text
View/download PDF

9. Delivery of Cancer Care at Home during the First COVID-19 Pandemic in Italy: A Case Series Study (DomOnCOVID Project)

Author

Passalacqua, Rodolfo, primary, Passalacqua, Rodolfo, additional, Ratti, Margherita, additional, Bonomi, Maria, additional, Grizzi, Giulia, additional, Negri, Federica, additional, Crea, Francesco, additional, Giganti, Mariaolga, additional, Perrucci, Bruno, additional, Brighenti, Matteo, additional, Panni, Stefano, additional, Donini, Maddalena, additional, Curti, Alessandra, additional, Spada, Daniele, additional, Marchi, Roberta, additional, Donati, Gianvito, additional, Saleri, Jessica, additional, Nazzari, Morena, additional, Pogliacomi, Giovanna, additional, Diodati, Francesca, additional, and Caminiti, Caterina, additional

Published
2021
Full Text
View/download PDF

11. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma

Author

Brunelli, Matteo, primary, Tafuri, Alessandro, additional, Cima, Luca, additional, Cerruto, Maria Angela, additional, Milella, Michele, additional, Zivi, Andrea, additional, Buti, Sebastiano, additional, Bersanelli, Melissa, additional, Fornarini, Giuseppe, additional, Vellone, Valerio Gaetano, additional, Rebuzzi, Sara Elena, additional, Procopio, Giuseppe, additional, Verzoni, Elena, additional, Bracarda, Sergio, additional, Sabbatini, Roberto, additional, Baldessari, Cinzia, additional, Eccher, Albino, additional, Passalacqua, Rodolfo, additional, Perrucci, Bruno, additional, Giganti, Maria Olga, additional, Donini, Maddalena, additional, Panni, Stefano, additional, Tucci, Marcello, additional, Prati, Veronica, additional, Ortega, Cinzia, additional, Caliò, Anna, additional, Alongi, Filippo, additional, Munari, Enrico, additional, Pappagallo, Giovanni, additional, Iacovelli, Roberto, additional, Mosca, Alessandra, additional, Porta, Camillo, additional, Martignoni, Guido, additional, and Antonelli, Alessandro, additional

Published
2020
Full Text
View/download PDF

13. Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer

Author

Caffo, Orazio, primary, Facchini, Gaetano, additional, Biasco, Elisa, additional, Ferraù, Francesco, additional, Morelli, Franco, additional, Donini, Maddalena, additional, Buttigliero, Consuelo, additional, Calvani, Nicola, additional, Guida, Annalisa, additional, Chiuri, Vincenzo Emanuele, additional, Basso, Umberto, additional, Mucciarini, Claudia, additional, Conteduca, Vincenza, additional, Rossetti, Sabrina, additional, Veccia, Antonello, additional, Maines, Francesca, additional, Kinspergher, Stefania, additional, and Giorgi, Ugo De, additional

Published
2019
Full Text
View/download PDF

14. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma

Author

Brunelli, Matteo, Tafuri, Alessandro, Cima, Luca, Cerruto, Maria Angela, Milella, Michele, Zivi, Andrea, Buti, Sebastiano, Bersanelli, Melissa, Fornarini, Giuseppe, Vellone, Valerio Gaetano, Rebuzzi, Sara Elena, Procopio, Giuseppe, Verzoni, Elena, Bracarda, Sergio, Sabbatini, Roberto, Baldessari, Cinzia, Eccher, Albino, Passalacqua, Rodolfo, Perrucci, Bruno, Giganti, Maria Olga, Donini, Maddalena, Panni, Stefano, Tucci, Marcello, Prati, Veronica, Ortega, Cinzia, Caliò, Anna, Alongi, Filippo, Munari, Enrico, Pappagallo, Giovanni, Iacovelli, Roberto, Mosca, Alessandra, Porta, Camillo, Martignoni, Guido, and Antonelli, Alessandro

Abstract

AimsAccording to The Cancer Genome Atlas (TCGA), around 9% of bladder carcinomas usually show abnormalities of the murine double minute 2 (MDM2) gene, but a few studies have been investigated them. We profiled MDM2 gene amplification in a series of urothelial carcinomas (UC) considering the molecular subtypes and expression of programmed death ligand 1 (PD-L1).Methods117 patients with muscle-invasive UC (pT2-3) without (N0) or with (N+) lymph-node metastases were revised. Only cases with availability of in toto specimens and follow-up were studied. Tissue microarray was built. p53, ER, RB1, GATA-3, CK20, CK5/6, CD44 and PD-L1 (clone sp263) immunoexpression was evaluated. Fluorescent in situ hybridisation was assessed by using the HER-2/neu, FGFR-3, CDKN2A and MDM2 probes. True (ratio 12q/CEP12 >2) MDM2 gene amplification was distinguished from polyploidy/gains (ratio <2, absolute copy number of MDM-2 >2). MDM2 and PD-L1 values were correlated to the TCGA molecular phenotypes. Statistical analysis was performed.Results6/50 (12%) cases (5 N0 and 1 N+) were amplified for MDM2 without matching to molecular phenotypes. Of 50, 14 (37%) cases expressed PD-L1 at 1% cut-off; 3/50 (9%) at >50% cut-off; of these, 2 cases on side of neoplasia among inflammatory cells. Only one out of six (17%) cases amplified for MDM2 showed expression (>50% cut-off) of PD-L1. MDM2 amplification was independent to all documented profiles (k test=0.3) and was prevalent in recurrent UC.ConclusionMDM2 amplification has been seen in both PD-L1 positive and negative muscle-invasive bladder UC independently from the TCGA molecular phenotypes. MDM2 and PD-L1 might be assessed in order to predict a better response to combo/single targeted therapies.

Published
2022
Full Text
View/download PDF

15. A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.

Author

Procopio, Giuseppe, primary, Cognetti, Francesco, additional, Miceli, Rosalba, additional, Milella, Michele, additional, Mosca, Alessandra, additional, Chiuri, Vincenzo Emanuele, additional, Bearz, Alessandra, additional, Morelli, Franco, additional, Ortega, Cinzia, additional, Atzori, Francesco, additional, Donini, Maddalena, additional, Ratta, Raffaele, additional, Martinetti, Antonia, additional, Montone, Rosanna, additional, De Braud, Filippo G., additional, Cappelletti, Vera, additional, and Verzoni, Elena, additional

Published
2018
Full Text
View/download PDF

16. Additional file 1: of Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01â 2014)

Author

Passalacqua, Rodolfo, Lazzarelli, Silvia, Donini, Maddalena, Montironi, Rodolfo, Tambaro, Rosa, Giorgi, Ugo De, Pignata, Sandro, Palumbo, Raffaella, Ceresoli, Giovanni, Conte, Gianluca Del, Tonini, Giuseppe, Morelli, Franco, Nolè, Franco, Panni, Stefano, Rondini, Ermanno, Guida, Annalisa, Zucali, Paolo, Doni, Laura, Iezzi, Elisa, and Caminiti, Caterina

Subjects
neoplasms
Abstract

List of participating centers. Table S1. Stratified analysis of overall survival (OS) and progression-free survival (PFS) according to previous Cisplatin or Carboplatin treatment and to the number of cycles received. (DOCX 46 kb)

Published
2017
Full Text
View/download PDF

18. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)

Author

Passalacqua, Rodolfo, primary, Lazzarelli, Silvia, additional, Donini, Maddalena, additional, Montironi, Rodolfo, additional, Tambaro, Rosa, additional, De Giorgi, Ugo, additional, Pignata, Sandro, additional, Palumbo, Raffaella, additional, Ceresoli, Giovanni Luca, additional, Del Conte, Gianluca, additional, Tonini, Giuseppe, additional, Morelli, Franco, additional, Nolè, Franco, additional, Panni, Stefano, additional, Rondini, Ermanno, additional, Guida, Annalisa, additional, Zucali, Paolo Andrea, additional, Doni, Laura, additional, Iezzi, Elisa, additional, and Caminiti, Caterina, additional

Published
2017
Full Text
View/download PDF

19. Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.

Author

Caffo, Orazio, primary, Bria, Emilio, additional, De Giorgi, Ugo, additional, Tucci, Marcello, additional, Galli, Luca, additional, Fratino, Lucia, additional, Rossetti, Sabrina, additional, Iacovelli, Roberto, additional, Lo Re, Giovanni, additional, Mosillo, Claudia, additional, Gasparro, Donatello, additional, Guglielmini, Pamela Francesca, additional, Damiani, Azzurra, additional, Procopio, Giuseppe, additional, De Lisi, Delia, additional, Ruatta, Fiorella, additional, Scagliarini, Sarah, additional, Donini, Maddalena, additional, Sperduti, Isabella, additional, and Basso, Umberto, additional

Published
2017
Full Text
View/download PDF

20. Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)- based third-line treatment: Final results from a multicenter Italian study.

Author

Caffo, Orazio, primary, Bria, Emilio, additional, De Giorgi, Ugo, additional, Tucci, Marcello, additional, Galli, Luca, additional, Fratino, Lucia, additional, Rossetti, Sabrina, additional, Iacovelli, Roberto, additional, Lo Re, Giovanni, additional, Mosillo, Claudia, additional, Gasparro, Donatello, additional, Guglielmini, Pamela, additional, Damiani, Azzurra, additional, Procopio, Giuseppe, additional, De Lisi, Delia, additional, Ortega, Cinzia, additional, Scagliarini, Sarah, additional, Donini, Maddalena, additional, Sperduti, Isabella, additional, and Basso, Umberto, additional

Published
2017
Full Text
View/download PDF

22. Vinflunine (VFL) in patients (pts) with metastatic transitional cell carcinoma of the urothelial tract (mTCCU): Clinical outcome and prognostic factors in a nationwide, real-life setting (MOVIE trial).

Author

Passalacqua, Rodolfo, primary, Lazzarelli, Silvia, additional, Montironi, Rodolfo, additional, Tambaro, Rosa, additional, De Giorgi, Ugo, additional, Bernardo, Antonio, additional, Ceresoli, Giovanni Luca, additional, Del Conte, Gianluca, additional, Donini, Maddalena, additional, Iezzi, Elisa, additional, Morelli, Franco, additional, Nole, Franco, additional, Panni, Stefano, additional, Perrucci, Bruno, additional, Rondini, Ermanno, additional, Sabbatini, Roberto, additional, Sequino, Manuel, additional, Tonini, Giuseppe, additional, Zucali, Paolo Andrea, additional, and Caminiti, Caterina, additional

Published
2016
Full Text
View/download PDF

23. Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC).

Author

Toppo, Laura, primary, Tomasello, Gianluca, additional, Liguigli, Wanda, additional, Lazzarelli, Silvia, additional, Tanzi, Giulia, additional, Ghidini, Michele, additional, Perrucci, Bruno, additional, Brighenti, Matteo, additional, Ratti, Margherita, additional, Panni, Stefano, additional, Giganti, Maria Olga, additional, Donini, Maddalena, additional, Rovatti, Massimo, additional, Maglietta, Giuseppe, additional, Ranieri, Valerio, additional, Grassia, Roberto, additional, Iiritano, Elena, additional, Iezzi, ELISA, additional, Caminiti, Caterina, additional, and Passalacqua, Rodolfo, additional

Published
2016
Full Text
View/download PDF

24. 1632 LONG TERM RESULTS WITH BLADDER-SPARING APPROACH IN MIBC

Author

Brighenti Matteo, Luigi Benecchi, Rodolfo Passalacqua, Daniel Martens, Domenico Potenzoni, Andrea Prati, Donini Maddalena, Nicoletta Uliano, Antonio Savino, Michele Potenzoni, Annamaria Pieri, and Sergio Carmelo Destro Pastizzaro

Subjects
medicine.medical_specialty, business.industry, Urology, Medicine, Long term results, Bladder sparing, business
Published
2013
Full Text
View/download PDF

25. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer

Author

Veccia, Antonello, primary, Caffo, Orazio, additional, De Giorgi, Ugo, additional, Di Lorenzo, Giuseppe, additional, Ortega, Cinzia, additional, Scognamiglio, Florinda, additional, Aieta, Michele, additional, Facchini, Gaetano, additional, Mansueto, Giovanni, additional, Mattioli, Rodolfo, additional, Procopio, Giuseppe, additional, Zagonel, Vittorina, additional, D'Angelo, Alessandro, additional, Spizzo, Gilbert, additional, Bortolus, Roberto, additional, Donini, Maddalena, additional, Lo Re, Giovanni, additional, Massari, Francesco, additional, Vicario, Giovanni, additional, Zucali, Paolo A, additional, Alesini, Daniele, additional, Bonetti, Andrea, additional, Mucciarini, Claudia, additional, Nicodemo, Maurizio, additional, Berruti, Alfredo, additional, Fratino, Lucia, additional, Lodde, Michele, additional, Messina, Caterina, additional, Perin, Alessandra, additional, Santini, Daniele, additional, Sava, Teodoro, additional, Tucci, Marcello, additional, Basso, Umberto, additional, Maines, Francesca, additional, Burgio, Luca S, additional, and Galligioni, Enzo, additional

Published
2016
Full Text
View/download PDF

26. Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study.

Author

Caffo, Orazio, primary, De Giorgi, Ugo, additional, Ferraú, Francesco, additional, Donini, Maddalena, additional, Facchini, Gaetano, additional, Maruzzo, Marco, additional, Tucci, Marcello, additional, Conteduca, Vincenza, additional, Maines, Francesca, additional, Rossi, Lorena, additional, Veccia, Antonello, additional, and Galligioni, Enzo, additional

Published
2016
Full Text
View/download PDF

27. Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.

Author

Maines, Francesca, primary, De Giorgi, Ugo, additional, Facchini, Gaetano, additional, Fratino, Lucia, additional, Gasparro, Donatello, additional, Alesini, Daniele, additional, Basso, Umberto, additional, Tucci, Marcello, additional, Ortega, Cinzia, additional, Scagliarini, Sarah, additional, Verderame, Francesco, additional, Barni, Sandro, additional, D'Angelo, Alessandro, additional, Vicario, Giovanni, additional, Donini, Maddalena, additional, Carrozza, Francesco, additional, Sava, Teodoro, additional, Sirotova, Zuzana, additional, Santini, Daniele, additional, and Caffo, Orazio, additional

Published
2016
Full Text
View/download PDF

28. Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study.

Author

Caffo, Orazio, primary, De Giorgi, Ugo, additional, Alesini, Daniele, additional, Fratino, Lucia, additional, Ortega, Cinzia, additional, Tucci, Marcello, additional, Scagliarini, Sarah, additional, Zagonel, Vittorina, additional, Zucali, Paolo Andrea, additional, Morelli, Franco, additional, Sartori, Donata, additional, Sabbatini, Roberto, additional, D'Angelo, Alessandro, additional, Donini, Maddalena, additional, Barni, Sandro, additional, Procopio, Giuseppe, additional, Sirotova, Zuzana, additional, Sava, Teodoro, additional, Conteduca, Vincenza, additional, and Galligioni, Enzo, additional

Published
2016
Full Text
View/download PDF

29. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients

Author

Conteduca, Vincenza, primary, Caffo, Orazio, additional, Fratino, Lucia, additional, Lo Re, Giovanni, additional, Basso, Umberto, additional, D'Angelo, Alessandro, additional, Donini, Maddalena, additional, Verderame, Francesco, additional, Ratta, Raffaele, additional, Procopio, Giuseppe, additional, Campadelli, Enrico, additional, Massari, Francesco, additional, Gasparro, Donatello, additional, Ermacora, Paola, additional, Messina, Caterina, additional, Giordano, Monica, additional, Alesini, Daniele, additional, Zagonel, Vittorina, additional, Veccia, Antonello, additional, Lolli, Cristian, additional, Maines, Francesca, additional, and De Giorgi, Ugo, additional

Published
2015
Full Text
View/download PDF

30. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

Author

Caffo, Orazio, primary, De Giorgi, Ugo, additional, Fratino, Lucia, additional, Alesini, Daniele, additional, Zagonel, Vittorina, additional, Facchini, Gaetano, additional, Gasparro, Donatello, additional, Ortega, Cinzia, additional, Tucci, Marcello, additional, Verderame, Francesco, additional, Campadelli, Enrico, additional, Lo Re, Giovanni, additional, Procopio, Giuseppe, additional, Sabbatini, Roberto, additional, Donini, Maddalena, additional, Morelli, Franco, additional, Sartori, Donata, additional, Zucali, Paolo, additional, Carrozza, Francesco, additional, D’Angelo, Alessandro, additional, Vicario, Giovanni, additional, Massari, Francesco, additional, Santini, Daniele, additional, Sava, Teodoro, additional, Messina, Caterina, additional, Fornarini, Giuseppe, additional, La Torre, Leonardo, additional, Ricotta, Riccardo, additional, Aieta, Michele, additional, Mucciarini, Claudia, additional, Zustovich, Fable, additional, Macrini, Sveva, additional, Burgio, Salvatore Luca, additional, Santarossa, Sandra, additional, D’Aniello, Carmine, additional, Basso, Umberto, additional, Tarasconi, Sara, additional, Cortesi, Enrico, additional, Buttigliero, Consuelo, additional, Ruatta, Fiorella, additional, Veccia, Antonello, additional, Conteduca, Vincenza, additional, Maines, Francesca, additional, and Galligioni, Enzo, additional

Published
2015
Full Text
View/download PDF

31. Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP).

Author

Conteduca, Vincenza, primary, Caffo, Orazio, additional, Fratino, Lucia, additional, Lo Re, Giovanni, additional, Basso, Umberto, additional, D'Angelo, Alessandro, additional, Donini, Maddalena, additional, Verderame, Francesco, additional, Ratta, Raffaele, additional, Procopio, Giuseppe, additional, Campadelli, Enrico, additional, Massari, Francesco, additional, Gasparro, Donatello, additional, Ermacora, Paola, additional, Messina, Caterina, additional, Giordano, Monica, additional, Alesini, Daniele, additional, Maines, Francesca, additional, and De Giorgi, Ugo, additional

Published
2015
Full Text
View/download PDF

32. Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.

Author

Caffo, Orazio, primary, De Giorgi, Ugo, additional, Facchini, Gaetano, additional, Fratino, Lucia, additional, Gasparro, Donatello, additional, Basso, Umberto, additional, Alesini, Daniele, additional, Tucci, Marcello, additional, Ortega, Cinzia, additional, Verderame, Francesco, additional, Procopio, Giuseppe, additional, Lo Re, Giovanni, additional, Campadelli, Enrico, additional, Omarini, Claudia, additional, Donini, Maddalena, additional, Morelli, Franco, additional, Zucali, Paolo A., additional, Sartori, Donata, additional, Conteduca, Vincenza, additional, and Galligioni, Enzo, additional

Published
2015
Full Text
View/download PDF

33. Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.

Author

Maruzzo, Marco, primary, Basso, Umberto, additional, Diminutto, Alberto, additional, De Giorgi, Ugo, additional, Fratino, Lucia, additional, Lo Re, Giovanni, additional, D'Angelo, Alessandro, additional, Donini, Maddalena, additional, Verderame, Francesco, additional, Ratta, Raffaele, additional, Procopio, Giuseppe, additional, Campadelli, Enrico, additional, Massari, Francesco, additional, Gasparro, Donatello, additional, Macrini, Sveva, additional, Messina, Caterina, additional, Giordano, Monica, additional, Maines, Francesca, additional, Zagonel, Vittorina, additional, and Caffo, Orazio, additional

Published
2015
Full Text
View/download PDF

34. Optimizing chemotherapy in patients with metastatic transitional-cell carcinoma: High rate of complete response with two sequential dose-dense regimens of cisplatin, gemcitabine, paclitaxel, followed by MVAC.

Author

Passalacqua, Rodolfo, primary, Giganti, Maria Olga, additional, Brighenti, Matteo, additional, Perrucci, Bruno, additional, Donini, Maddalena, additional, Negri, Federica, additional, Tomasello, Gianluca, additional, Toppo, Laura, additional, Liguigli, Wanda, additional, Poli, Rossana, additional, Ratti, Margherita, additional, Benecchi, Luigi, additional, Prati, Andrea, additional, Arnaudi, Roberto, additional, Potenzoni, Michele, additional, Panni, Stefano, additional, and Lazzarelli, Silvia, additional

Published
2015
Full Text
View/download PDF

35. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme

Author

Caffo, Orazio, primary, De Giorgi, Ugo, additional, Fratino, Lucia, additional, Lo Re, Giovanni, additional, Basso, Umberto, additional, D'Angelo, Alessandro, additional, Donini, Maddalena, additional, Verderame, Francesco, additional, Ratta, Raffaele, additional, Procopio, Giuseppe, additional, Campadelli, Enrico, additional, Massari, Francesco, additional, Gasparro, Donatello, additional, Macrini, Sveva, additional, Messina, Caterina, additional, Giordano, Monica, additional, Alesini, Daniele, additional, Zustovich, Fable, additional, Fraccon, Anna P., additional, Vicario, Giovanni, additional, Conteduca, Vincenza, additional, Maines, Francesca, additional, and Galligioni, Enzo, additional

Published
2014
Full Text
View/download PDF

36. Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.

Author

Caffo, Orazio, primary, Basso, Umberto, additional, Facchini, Gaetano, additional, Gasparro, Donatello, additional, Alesini, Daniele, additional, Tucci, Marcello, additional, Ortega, Cinzia, additional, Fratino, Lucia, additional, Campadelli, Enrico, additional, Lo Re, Giovanni, additional, Sabbatini, Roberto, additional, Procopio, Giuseppe, additional, Zucali, Paolo A., additional, D'Angelo, Alessandro, additional, Donini, Maddalena, additional, Massari, Francesco, additional, Ratta, Raffaele, additional, Sava, Teodoro, additional, Messina, Caterina, additional, and De Giorgi, Ugo, additional

Published
2014
Full Text
View/download PDF

37. Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.

Author

Caffo, Orazio, primary, Fratino, Lucia, additional, Lo Re, Giovanni, additional, Basso, Umberto, additional, D'Angelo, Alessandro, additional, Donini, Maddalena, additional, Santini, Daniele, additional, Procopio, Giuseppe, additional, Massari, Francesco, additional, Gasparro, Donatello, additional, Verderame, Francesco, additional, Sacco, Cosimo, additional, Messina, Caterina, additional, Iacovelli, Roberto, additional, Zustovich, Fable, additional, Vicario, Giovanni, additional, Fraccon, Anna Paola, additional, Conteduca, Vincenza, additional, Maines, Francesca, additional, and De Giorgi, Ugo, additional

Published
2014
Full Text
View/download PDF

38. Efficacy and safety of dose-dense modified TCF regimen (TCF-dd) in metastatic or locally advanced gastroesophageal cancer (GEC).

Author

Toppo, Laura, primary, Tomasello, Gianluca, additional, Liguigli, Wanda, additional, Ratti, Margherita, additional, Poli, Rossana, additional, Negri, Federica, additional, Curti, Alessandra, additional, Vismarra, Marco, additional, Maltese, Mariangela, additional, Delfrate, Roberto, additional, Donini, Maddalena, additional, Colombi, Chiara, additional, Brighenti, Matteo, additional, Panni, Stefano, additional, Perrucci, Bruno, additional, Lazzarelli, Silvia, additional, and Passalacqua, Rodolfo, additional

Published
2013
Full Text
View/download PDF

39. Clinical outcome (CO) and predictive factors (PRE) evaluation of a cohort of castration resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA) in a named patient program (NPP): Preliminary results from a retrospective study.

Author

Veccia, Antonello, primary, Fratino, Lucia, additional, Basso, Umberto, additional, Donini, Maddalena, additional, D'Angelo, Alessandro, additional, Massari, Francesco, additional, Procopio, Giuseppe, additional, Gasparro, Donatello, additional, Verderame, Francesco, additional, Messina, Caterina, additional, Zustovich, Fable, additional, Iacovelli, Roberto, additional, Fraccon, Anna Paola, additional, Pappagallo, Giovanni L., additional, Maines, Francesca, additional, Caffo, Orazio, additional, and Galligioni, Enzo, additional

Published
2013
Full Text
View/download PDF

40. Final analysis of efficacy and safety of dose-dense chemotherapy with modified TCF regimen (TCF-dd) in elderly patients (pts) with metastatic gastric cancer (MGC).

Author

Tomasello, Gianluca, primary, Liguigli, Wanda, additional, Poli, Rossana, additional, Ratti, Margherita, additional, Toppo, Laura, additional, Brighenti, Matteo, additional, Maltese, Mariangela, additional, Perrucci, Bruno, additional, Panni, Stefano, additional, Negri, Federica, additional, Lazzarelli, Silvia, additional, Colombi, Chiara, additional, Curti, Alessandra, additional, Donini, Maddalena, additional, Martinotti, Mario, additional, Rovatti, Massimo, additional, and Passalacqua, Rodolfo, additional

Published
2013
Full Text
View/download PDF

41. Rate of durable complete remission (CR) using two sequential, dose-dense regimens of cisplatin, gemcitabine, paclitaxel (CGP) followed by m-VAC in patients with metastatic urothelial cancer (mUC).

Author

Brighenti, Matteo, primary, Panni, Stefano, additional, Perrucci, Bruno, additional, Maltese, Mariangela, additional, Liguigli, Wanda, additional, Tomasello, Gianluca, additional, Poli, Rossana, additional, Negri, Federica, additional, Ratti, Margherita, additional, Donini, Maddalena, additional, Toppo, Laura, additional, del Boca, Carlo, additional, Benecchi, Luigi, additional, Prati, Andrea, additional, Martens, Daniel, additional, Potenzoni, Michele, additional, and Passalacqua, Rodolfo, additional

Published
2013
Full Text
View/download PDF

43. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by oxaliplatin, folinic acid, 5-fluorouracil, and irinotecan (COFFI) in locally advanced or metastatic gastric cancer (MGC).

Author

Tomasello, Gianluca, primary, Liguigli, Wanda, additional, Poli, Rossana, additional, Negri, Federica, additional, Brighenti, Matteo, additional, Toppo, Laura, additional, Curti, Alessandra, additional, Lazzarelli, Silvia, additional, Panni, Stefano, additional, Donini, Maddalena, additional, Maltese, Mariangela, additional, Ratti, Margherita, additional, and Passalacqua, Rodolfo, additional

Published
2012
Full Text
View/download PDF

46. Dose-finding Trial of a Combined Regsimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study

Author

Buti, Sebastiano, primary, Lazzarelli, Silvia, additional, Chiesa, Matteo Dalla, additional, Simonelli, Cecilia, additional, Lo Re, Giovanni, additional, Lheshi, Arvin, additional, Simon, Spazzapan, additional, Mattioli, Rodolfo, additional, Caminiti, Caterina, additional, Mazza, Giancarlo, additional, Donini, Maddalena, additional, and Passalacqua, Rodolfo, additional

Published
2010
Full Text
View/download PDF

48. PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER (MCRPC) PATIENTS RECEIVING A NEW AGENT (NA)-BASED THIRD-LINE TREATMENT. FINAL RESULTS FROM A MULTICENTER ITALIAN STUDY

Author

Caffo, Orazio, Bria, Emilio, Giorgi, Ugo, Tucci, Marcello, Galli, Luca, Fratino, Lucia, Facchini, Gaetano, Iacovelli, Roberto, Lo Re, Giovanni, Mosillo, Claudia, Gasparro, Donatello, Guglielmini, Pamela, Damiani, Azzurra, Procopio, Giuseppe, Lisi, Delia, Ortega, Cinzia, Scagliarini, Sarah, Donini, Maddalena, Isabella Sperduti, and Basso, Umberto

49. Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study

Author

Matteo Brunelli, Guido Martignoni, Giorgio Malpeli, Alessandro Volpe, Luca Cima, Maria Rosaria Raspollini, Mattia Barbareschi, Alessandro Tafuri, Giulia Masi, Luisa Barzon, Serena Ammendola, Manuela Villanova, Maria Angela Cerruto, Michele Milella, Sebastiano Buti, Melissa Bersanelli, Giuseppe Fornarini, Sara Elena Rebuzzi, Valerio Gaetano Vellone, Gabriele Gaggero, Giuseppe Procopio, Elena Verzoni, Sergio Bracarda, Martina Fanelli, Roberto Sabbatini, Rodolfo Passalacqua, Bruno Perrucci, Maria Olga Giganti, Maddalena Donini, Stefano Panni, Marcello Tucci, Veronica Prati, Cinzia Ortega, Anna Caliò, Albino Eccher, Filippo Alongi, Giovanni Pappagallo, Roberto Iacovelli, Alessandra Mosca, Paolo Umari, Ilaria Montagnani, Stefano Gobbo, Francesco Atzori, Enrico Munari, Marco Maruzzo, Umberto Basso, Francesco Pierconti, Carlo Patriarca, Piergiuseppe Colombo, Alberto Lapini, Giario Conti, Roberto Salvioni, Enrico Bollito, Andrea Cossarizza, Francesco Massari, Mimma Rizzo, Renato Franco, Federica Zito-Marino, Yoseba Aberasturi Plata, Francesca Galuppini, Marta Sbaraglia, Matteo Fassan, Angelo Paolo Dei Tos, Maurizio Colecchia, Holger Moch, Maurizio Scaltriti, Camillo Porta, Brett Delahunt, Gianluca Giannarini, Roberto Bortolus, Pasquale Rescigno, Giuseppe Luigi Banna, Alessio Signori, Miguel Angel Llaja Obispo, Roberto Perris, Alessandro Antonelli, Brunelli, Matteo, Martignoni, Guido, Malpeli, Giorgio, Volpe, Alessandro, Cima, Luca, Raspollini, Maria Rosaria, Barbareschi, Mattia, Tafuri, Alessandro, Masi, Giulia, Barzon, Luisa, Ammendola, Serena, Villanova, Manuela, Cerruto, Maria Angela, Milella, Michele, Buti, Sebastiano, Bersanelli, Melissa, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Vellone, Valerio Gaetano, Gaggero, Gabriele, Procopio, Giuseppe, Verzoni, Elena, Bracarda, Sergio, Fanelli, Martina, Sabbatini, Roberto, Passalacqua, Rodolfo, Perrucci, Bruno, Giganti, Maria Olga, Donini, Maddalena, Panni, Stefano, Tucci, Marcello, Prati, Veronica, Ortega, Cinzia, Caliò, Anna, Eccher, Albino, Alongi, Filippo, Pappagallo, Giovanni, Iacovelli, Roberto, Mosca, Alessandra, Umari, Paolo, Montagnani, Ilaria, Gobbo, Stefano, Atzori, Francesco, Munari, Enrico, Maruzzo, Marco, Basso, Umberto, Pierconti, Francesco, Patriarca, Carlo, Colombo, Piergiuseppe, Lapini, Alberto, Conti, Giario, Salvioni, Roberto, Bollito, Enrico, Cossarizza, Andrea, Massari, Francesco, Rizzo, Mimma, Franco, Renato, Zito-Marino, Federica, Aberasturi Plata, Yoseba, Galuppini, Francesca, Sbaraglia, Marta, Fassan, Matteo, Dei Tos, Angelo Paolo, Colecchia, Maurizio, Moch, Holger, Scaltriti, Maurizio, Porta, Camillo, Delahunt, Brett, Giannarini, Gianluca, Bortolus, Roberto, Rescigno, Pasquale, Banna, Giuseppe Luigi, Signori, Alessio, Obispo, Miguel Angel Llaja, Perris, Roberto, Antonelli, Alessandro, Brunelli M., Martignoni G., Malpeli G., Volpe A., Cima L., Raspollini M.R., Barbareschi M., Tafuri A., Masi G., Barzon L., Ammendola S., Villanova M., Cerruto M.A., Milella M., Buti S., Bersanelli M., Fornarini G., Rebuzzi S.E., Vellone V.G., Gaggero G., Procopio G., Verzoni E., Bracarda S., Fanelli M., Sabbatini R., Passalacqua R., Perrucci B., Giganti M.O., Donini M., Panni S., Tucci M., Prati V., Ortega C., Calio A., Eccher A., Alongi F., Pappagallo G., Iacovelli R., Mosca A., Umari P., Montagnani I., Gobbo S., Atzori F., Munari E., Maruzzo M., Basso U., Pierconti F., Patriarca C., Colombo P., Lapini A., Conti G., Salvioni R., Bollito E., Cossarizza A., Massari F., Rizzo M., Franco R., Zito-Marino F., Plata Y.A., Galuppini F., Sbaraglia M., Fassan M., Dei Tos A.P., Colecchia M., Moch H., Scaltriti M., Porta C., Delahunt B., Giannarini G., Bortolus R., Rescigno P., Banna G.L., Signori A., Obispo M.A.L., Perris R., and Antonelli A.

Subjects
angiogenesis, clear cell renal cell carcinoma, tumor sampling, intratumoral heterogeneity, immunity, immunohistochemistry, Medicine (miscellaneous), angiogenesi
Abstract

We aimed to overcome intratumoral heterogeneity in clear cell renal cell carcinoma (clearRCC). One hundred cases of clearRCC were sampled. First, usual standard sampling was applied (1 block/cm of tumor); second, the whole tumor was sampled, and 0.6 mm cores were taken from each block to construct a tissue microarray; third, the residual tissue, mapped by taking pieces 0.5 × 0.5 cm, reconstructed the entire tumor mass. Precisely, six randomly derived pieces of tissues were placed in each cassette, with the number of cassettes being based on the diameter of the tumor (called multisite 3D fusion). Angiogenic and immune markers were tested. Routine 5231 tissue blocks were obtained. Multisite 3D fusion sections showed pattern A, homogeneous high vascular density (10%), pattern B, homogeneous low vascular density (8%) and pattern C, heterogeneous angiogenic signatures (82%). PD-L1 expression was seen as diffuse (7%), low (33%) and absent (60%). Tumor-infiltrating CD8 scored high in 25% (pattern hot), low in 65% (pattern weak) and zero in 10% of cases (pattern desert). Grading was upgraded in 26% of cases (G3–G4), necrosis and sarcomatoid/rhabdoid characters were observed in, respectively, 11 and 7% of cases after 3D fusion (p = 0.03). CD8 and PD-L1 immune expressions were higher in the undifferentiated G4/rhabdoid/sarcomatoid clearRCC subtypes (p = 0.03). Again, 22% of cases were set to intermediate to high risk of clinical recurrence due to new morphological findings of all aggressive G4, sarcomatoid/rhabdoid features by using 3D fusion compared to standard methods (p = 0.04). In conclusion, we propose an easy-to-apply multisite 3D fusion sampling that negates bias due to tumor heterogeneity.

Published
2022

50. Systemic adjuvant therapies in renal cell carcinoma

Author

Sebastiano Buti, Andrea Ardizzoni, Melissa Bersanelli, Maddalena Donini, Buti, Sebastiano, Bersanelli, Melissa, Donini, Maddalena, and Ardizzoni, Andrea

Subjects
Oncology, medicine.medical_specialty, Pathology, renal cell carcinoma, lcsh:Internal medicine, Cancer Research, medicine.medical_treatment, Phases of clinical research, Disease, Review, Renal cell carcinoma, Internal medicine, Adjuvant therapy, Medicine, Radical surgery, lcsh:RC31-1245, business.industry, adjuvant therapy, lcsh:Other systems of medicine, medicine.disease, lcsh:RZ201-999, Nephrectomy, immunotherapy, Clinical trial, Immunotherapy, business, Adjuvant
Abstract

Renal cell carcinoma (RCC) is one of the ten most frequent solid tumors worldwide. Recent innovations in the treatment of metastatic disease have led to new therapeutic approaches being investigated in the adjuvant setting. Observation is the only current standard of care after radical nephrectomy, although there is evidence of efficacy of adjuvant use of vaccine among all the strategies used. This article aims to collect published experiences with systemic adjuvant approaches in RCC and to describe the results of past and ongoing phase III clinical trials in this field. We explored all the systemic treatments, including chemotherapy, immunotherapy and targeted drugs while alternative approaches have also been described. Appropriate selection of patients who would benefit from adjuvant therapies remains a crucial dilemma. Although the international guidelines do not actually recommend any adjuvant treatment after radical surgery for RCC, no conclusions have yet been drawn pending the results of the promising ongoing clinical trials with the target therapies. The significant changes that these new drugs have made on advanced disease outcome could represent the key to innovation in terms of preventing recurrence, delaying relapse and prolonging survival after radical surgery for RCC. © Copyright S. Buti et al., 2012.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results